Skip to content

New data on lecanemab presented at the CTAD Alzheimer conference

BioArctic and partner Eisai held several oral presentations at the 14th Clinical Trials on Alzheimer’s Disease (CTAD) conference, November 9-12, 2021, revealing new data on Lecanemab back-up, an investigational anti-amyloid beta protofibril antibody. The presentations provided further support for the encouraging data regarding lecanemab’s potential as a treatment for early Alzheimer’s disease previously seen in the Phase 2b as well as open label extension study. In addition, data presented showed the potential to use blood tests with p-tau181 and Aβ42/40 to monitor treatment effect of lecanemab. Data presented also clarified similarities and differences in the binding profiles of lecanemab compared to other late-stage anti-amyloid antibodies for Alzheimer’s disease.